I noticed in today’s pr, it clearly said ‘if the iikey peptides work’ they expected to ink development deals outside the US. So publicly speaking, they are not ready to state that the iikey peptides work. It’s still an open question, and I suppose there has to be a level of research certainty that must be established before they can say ‘we think it works’, permitting them to set off down the vaccine path. So I’m not holding my breath on any of these preliminary contracts. First things first: investigational results must precede any inked agreements. Like the S-1’s, this step cannot be rushed. Like the SEC, the peptides have a ‘mind of their own’, just like the covid virus, and won’t respond to politics, investor impatience for results etc etc. I thought that having to ‘practice patience’ would end as soon as the S-1’s were approved. But it looks like...shucks!...that I’ll have to practice patience for a bit longer.